EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Matched comparison of therapeutic DLI and second allogeneic transplantation after relapse of acute leukemia or MDS

Alexander C. Angleitner, Markus Maulhardt, Justin Hasenkamp, Judith Büntzel, Gerald Wulf

Frontiers in Hematology · 11.06.2026 · 5

DOI: 10.3389/frhem.2026.1826416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Hematology, online erschienen am 11.06.2026. Verfasst von Alexander C. Angleitner und 4 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Relapse is the main cause of treatment failure after allogeneic hematopoietic cell transplantation (allo-HCT). Therapeutic donor lymphocyte infusion (DLI) and second allo-HCT are common post-relapse options, but comparative evidence from the time of relapse is limited.

Methods

We retrospectively analyzed 85 adults with acute leukemia or myelodysplastic syndromes (MDS) who received therapeutic DLI or a second allo-HCT after relapse (2010–2022). DLI required hematologic or clinical relapse. Overall survival (OS) was assessed using Kaplan–Meier analysis, Cox regression, and propensity score matching (PSM). Competing risks models evaluated relapse-related mortality (RRM) and non-relapse mortality (NRM).

Results

60 patients received DLI and 25 underwent a second allo-HCT. No significant difference in OS was observed between groups (median OS 0.92 vs. 0.61 years, p=0.295). DLI showed higher RRM, while second allo-HCT showed a trend toward higher NRM. In the matched cohort (n = 36), OS remained numerically longer after second allo-HCT without significance.

Conclusion

OS did not differ between second allo-HCT and therapeutic DLI. Treatment should be individualized, and larger multicenter studies are needed to refine patient selection.

Zitieren

APA

Angleitner, A. C., Maulhardt, M., Hasenkamp, J., Büntzel, J., & Wulf, G. (2026). Matched comparison of therapeutic DLI and second allogeneic transplantation after relapse of acute leukemia or MDS. Frontiers in Hematology, 5. https://doi.org/10.3389/frhem.2026.1826416

Vancouver

Angleitner AC, Maulhardt M, Hasenkamp J, Büntzel J, Wulf G. Matched comparison of therapeutic DLI and second allogeneic transplantation after relapse of acute leukemia or MDS. Frontiers in Hematology. 2026;5. doi:10.3389/frhem.2026.1826416

BibTeX
@article{Angleitner2026,
  author = {Angleitner, Alexander C. and Maulhardt, Markus and Hasenkamp, Justin and Büntzel, Judith and Wulf, Gerald},
  title = {Matched comparison of therapeutic DLI and second allogeneic transplantation after relapse of acute leukemia or MDS},
  journal = {Frontiers in Hematology},
  year = {2026},
  volume = {5},
  doi = {10.3389/frhem.2026.1826416}
}
Kostenlos starten →